# RemeGen

Next-gen biologics — High-efficacy payloads.

Source: https://en.bioecon.ru/companies/remegen/
Updated: 2026-07-02

- Country: China

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Revenue | RMB 5,850.2 million for the six months ended June 30, 2026 | https://quartr.com/events/remegen-co-ltd-9995-q2-2026_F1LMGYsM, https://www.hkexnews.hk/listedco/listconews/sehk/2026/0824/2026082401967.pdf |
| Capacity | 36,000L as of end of 2021; planned expansion to 80,000L before 2025 | https://hk-official.cmbi.info/upload/32ccc4b2-b96f-41fb-8fdd-eabf3c425fb1.pdf, https://pdf.dfcfw.com/pdf/H3_AP202211041579914299_1.pdf |
| Headcount | 3,146 employees as of June 30, 2026 | https://www.hkexnews.hk/listedco/listconews/sehk/2026/0824/2026082401967.pdf |
| Production site | Yantai, Shandong, China | https://hk-official.cmbi.info/upload/32ccc4b2-b96f-41fb-8fdd-eabf3c425fb1.pdf, https://pdf.dfcfw.com/pdf/H3_AP202211041579914299_1.pdf |
| Regulatory approval | Telitacicept (SLE, RA, gMG); Disitamab vedotin (GC, UC, advanced breast cancer) in China | https://ir.vorbio.com/news-releases/news-release-details/vor-bio-enters-exclusive-global-license-agreement-remegen-late, https://www.remegen.com/uploadfile/2025/12/10/1852a7b04bedcee16d58b298637feee16938bb5d48934.pdf, https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0428/2026042800854.pdf |

Independent sources: hk-official.cmbi.info, hkexnews.hk, ir.vorbio.com, pdf.dfcfw.com, quartr.com, www1.hkexnews.hk

## Technologies

- [Antibody-drug conjugates (ADCs)](https://en.bioecon.ru/technology/antibody-drug-conjugates-adcs/)